NCT03730363
- Conditions
- Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +8 more
- Locations
-
- University of Kentucky Markey Cancer Center Lexington, Kentucky, United States
Clinical trial condition
Refractory Hodgkin Lymphoma
Explore clinical trials studying Refractory Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.
34 public trials
5 recruiting studies
Refractory Hodgkin Lymphoma trial results
NCT02181478
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Bone Marrow Diseases, +35 more
- Locations
-
- Case Comprehensive Cancer Center Cleveland, Ohio, United States
NCT01921387
- Conditions
- Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +18 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +49 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
- Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States
- Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States
NCT00005803
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +33 more
- Locations
-
- Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
- LDS Hospital Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
NCT00723099
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
- Locations
-
- University of Colorado Hospital Aurora, Colorado, United States
- Colorado Blood Cancer Institute Denver, Colorado, United States
- LDS Hospital Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
Completed
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897012
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +36 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT01393717
- Conditions
- Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Weill Medical College, Cornell University New York, United States
NCT00075478
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma, +48 more
- Locations
-
- OHSU Cancer Institute-Southern Region Medford, Oregon, United States
- Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
- LDS Hospital Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
Active, Not Recruiting
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
NCT03016871
- Conditions
- Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Yale University New Haven, Connecticut, United States
- M D Anderson Cancer Center Houston, Texas, United States
- Fred Hutchinson Cancer Research Center Seattle, Washington, United States